Taysha Gene Therapies, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $12.00 price target.

End of Quarter Sale - 70% Off

• Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
• Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Gil Blum has given his Buy rating due to a combination of factors related to data quality, trial design, and safety differentiation versus a key competitor. He emphasizes that Neurogene’s Phase I/II outcomes were judged using an unblinded review process, which can introduce bias and makes those results less reliable when compared with Taysha’s blinded assessments.

Blum also notes that Neurogene incorporates additional developmental milestones that are not derived from the established Rett natural history framework used in Taysha’s pivotal programs, complicating like‑for‑like comparisons. Combined with concerns over Neurogene’s post‑hoc baseline score changes and emerging safety signals suggestive of potential DRG toxicity, he views Taysha’s dataset and trial rigor as comparatively stronger, supporting a Buy rating and an unchanged $12 price target.

Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Lyell Immunopharma, and Cartesian Therapeutics. According to TipRanks, Blum has an average return of 16.2% and a 46.08% success rate on recommended stocks.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.